Document Detail


Mechanisms of Antiangiogenic-Induced Arterial Hypertension.
MedLine Citation:
PMID:  21479992     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Antiangiogenic therapy has emerged as an important concept in the treatment of solid tumors. Vascular endothelial growth factor (VEGF) represents an important therapeutic target, as it is the primary mediator of angiogenesis and is induced by multiple tumor-relevant stimuli. Arterial hypertension has been commonly reported in all clinical trials testing inhibitors of angiogenesis (especially inhibitors of VEGF/VEGFR-2 signalling), with incidence ranging from 11% to 43% in all studies. The mechanism of elevated blood pressure in patients treated with antiangiogenic agents is not fully understood, but it is probably multifactorial, involving endothelial dysfunction and capillary rarefaction. Recently, several studies have suggested that early blood pressure rise was associated with better antitumoral efficacy and improved prognosis, making this commonly observed effect a promising marker of efficacy.
Authors:
Jean-Jacques Mourad; Bernard I Levy
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-12
Journal Detail:
Title:  Current hypertension reports     Volume:  -     ISSN:  1534-3111     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Internal Medicine and Arterial Hypertension, Avicenne Hospital, 125 Rue de Stalingrad, 93000, Bobigny, France, jean-jacques.mourad@avc.aphp.fr.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modular Design, Expression and Characterization of Novel Bifunctional Mutants of Fibrolase with Comb...
Next Document:  The Optimal Chemotherapy for Stage III Non-Small Cell Lung Cancer Patients.